MA27177A1 - Synthese controlee de ziprasidone et compositions en contenant. - Google Patents
Synthese controlee de ziprasidone et compositions en contenant.Info
- Publication number
- MA27177A1 MA27177A1 MA27827A MA27827A MA27177A1 MA 27177 A1 MA27177 A1 MA 27177A1 MA 27827 A MA27827 A MA 27827A MA 27827 A MA27827 A MA 27827A MA 27177 A1 MA27177 A1 MA 27177A1
- Authority
- MA
- Morocco
- Prior art keywords
- ziprasidone
- compositions
- container
- chloroziprasidone
- february
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title abstract 4
- 229960000607 ziprasidone Drugs 0.000 title abstract 4
- 230000015572 biosynthetic process Effects 0.000 title abstract 3
- 238000003786 synthesis reaction Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Indole Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 20 Février 2002 60/358,806 US 21 Février 2002 60/359,038 US 27 février 2002 60/360,459 Voir en annexe le titre de l'invention et le texte de l'abrégé Synthèse contrôlée de ziprasidone et compositions en contenant La présente invention propose une composition de ziprasidone qui comprend une quantité non supérieure à 1000 ppm de des-chloroziprasidone, avantageusement non supérieure à environ 500 ppm de des-chloroziprasidone, et plus avantageusement non supérieure à environ 100 ppm de des-chloroziprasidone. Des procédés pour la synthèse et l'utilisation de ces compositions de ziprasidone sont également proposés.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35880602P | 2002-02-20 | 2002-02-20 | |
| US35903802P | 2002-02-21 | 2002-02-21 | |
| US36045902P | 2002-02-27 | 2002-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27177A1 true MA27177A1 (fr) | 2005-01-03 |
Family
ID=27761437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27827A MA27177A1 (fr) | 2002-02-20 | 2004-08-17 | Synthese controlee de ziprasidone et compositions en contenant. |
Country Status (41)
| Country | Link |
|---|---|
| EP (1) | EP1476162B1 (fr) |
| JP (1) | JP4554938B2 (fr) |
| KR (1) | KR100773622B1 (fr) |
| CN (2) | CN1635892A (fr) |
| AP (1) | AP2004003103A0 (fr) |
| AR (1) | AR038563A1 (fr) |
| AT (1) | ATE359787T1 (fr) |
| AU (2) | AU2003206035A1 (fr) |
| BR (1) | BR0307833A (fr) |
| CA (1) | CA2475302C (fr) |
| CO (1) | CO5611138A2 (fr) |
| CY (1) | CY1106467T1 (fr) |
| DE (1) | DE60313289T2 (fr) |
| DK (1) | DK1476162T3 (fr) |
| EA (1) | EA007866B1 (fr) |
| EC (1) | ECSP045239A (fr) |
| ES (1) | ES2283745T3 (fr) |
| GE (1) | GEP20074030B (fr) |
| GT (1) | GT200300040A (fr) |
| HR (1) | HRP20040711A2 (fr) |
| IL (1) | IL163277A (fr) |
| IS (1) | IS7344A (fr) |
| MA (1) | MA27177A1 (fr) |
| MX (1) | MXPA04006993A (fr) |
| MY (1) | MY139523A (fr) |
| NO (2) | NO20043902L (fr) |
| NZ (1) | NZ534443A (fr) |
| OA (1) | OA12774A (fr) |
| PA (1) | PA8567001A1 (fr) |
| PE (1) | PE20030942A1 (fr) |
| PL (1) | PL372238A1 (fr) |
| PT (1) | PT1476162E (fr) |
| RS (1) | RS60404A (fr) |
| SI (1) | SI1476162T1 (fr) |
| SV (1) | SV2004001485A (fr) |
| TN (1) | TNSN04159A1 (fr) |
| TW (1) | TW200307546A (fr) |
| UA (1) | UA77057C2 (fr) |
| UY (1) | UY27668A1 (fr) |
| WO (1) | WO2003070246A1 (fr) |
| ZA (1) | ZA200406276B (fr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2397981C (fr) | 2000-03-06 | 2010-12-21 | Acadia Pharmaceuticals, Inc. | Composes azacycliques utilises dans le traitement de maladies liees a la serotonine |
| EP1461339B1 (fr) | 2001-12-28 | 2010-04-28 | Acadia Pharmaceuticals Inc. | Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine |
| US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| IL165907A0 (en) | 2002-06-24 | 2006-01-15 | Acadia Pharm Inc | N-substituted piperidine derivatives as serotonin receptor agents |
| US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
| WO2004050655A1 (fr) * | 2002-12-04 | 2004-06-17 | Dr. Reddy's Laboratories Limited | Formes polymorphes de ziprasidone et son chlorhydrate |
| US7488729B2 (en) | 2002-12-04 | 2009-02-10 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof |
| CN1816524B (zh) | 2003-01-16 | 2012-06-27 | 阿卡蒂亚药品公司 | 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂 |
| DE602004013405T2 (de) | 2003-03-17 | 2009-05-07 | Teva Pharmaceutical Industries Ltd. | Polymorphe formen von valsartan |
| US7199144B2 (en) | 2003-04-21 | 2007-04-03 | Teva Pharmaceuticals Industries, Ltd. | Process for the preparation of valsartan and intermediates thereof |
| WO2004094392A1 (fr) * | 2003-04-21 | 2004-11-04 | Teva Pharmaceutical Industries Ltd. | Processus de preparation de valsartan |
| KR20060015750A (ko) | 2003-06-03 | 2006-02-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법 |
| WO2005040160A2 (fr) | 2003-10-24 | 2005-05-06 | Teva Pharmaceutical Industries Ltd. | Procedes de preparation de ziprasidone |
| CN1934108A (zh) * | 2003-12-18 | 2007-03-21 | 特瓦制药工业有限公司 | 齐拉西酮碱的多晶型b2 |
| US20080312254A1 (en) | 2004-02-27 | 2008-12-18 | Ranbaxy Laboratories Limited | Process for the Preparation of Ziprasidone |
| CA2467538C (fr) | 2004-05-14 | 2010-08-24 | Apotex Pharmachem Inc. | Nouveau chlorhydrate de ziprasidone amorphe (chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydr o-2h-indol-2-one) et procedes pour sa production |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| CA2471219A1 (fr) | 2004-06-14 | 2005-12-14 | Apotex Pharmachem Inc. | Preparation amelioree d'une forme anhydre du chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one (chlorhydrate de ziprasidone) |
| US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| CN102153505B (zh) | 2004-09-27 | 2014-10-22 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐的合成和晶形 |
| ES2250001B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Proceso para la purificacion de ziprasidona. |
| ES2250000B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Procedimiento para la preparacion de ziprasidona. |
| WO2006080025A1 (fr) * | 2005-01-27 | 2006-08-03 | Hetero Drugs Limited | Procédé de synthèse de la ziprasidone impliquant de nouveaux intermédiaires |
| ITMI20052216A1 (it) * | 2005-11-18 | 2007-05-19 | Dipharma Spa | Procedimento per la preparazione di ziprasidone |
| CN100491375C (zh) * | 2006-07-01 | 2009-05-27 | 浙江美诺华药物化学有限公司 | 一种齐拉西酮的制备方法 |
| US20090053329A1 (en) | 2007-03-19 | 2009-02-26 | Acadia Pharmaceuticals, Inc. | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
| CN102234272A (zh) * | 2010-04-21 | 2011-11-09 | 上海医药工业研究院 | 盐酸齐拉西酮半水合物的制备方法 |
| CN102234273B (zh) * | 2010-04-21 | 2015-08-05 | 上海医药工业研究院 | 甲磺酸齐拉西酮半水合物及其制备方法 |
| SI3325444T1 (sl) | 2015-07-20 | 2021-11-30 | Acadia Pharmaceuticals Inc. | Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C |
| WO2017165635A1 (fr) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Association de pimavansérine et de modulateurs du cytochrome p450 |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| WO2018118626A1 (fr) | 2016-12-20 | 2018-06-28 | Acadia Pharmaceuticals Inc. | Pimavansérine seule ou en association pour une utilisation dans le traitement de la psychose liée à la maladie d'alzheimer |
| CN108239085A (zh) * | 2016-12-26 | 2018-07-03 | 四川科瑞德凯华制药有限公司 | 一种甲磺酸齐拉西酮的纯化及制备方法 |
| US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| EP3675827A1 (fr) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations de pimavansérine |
| CN112724066B (zh) * | 2021-02-04 | 2022-10-21 | 海南鑫开源医药科技有限公司 | 一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法 |
| CN116046966A (zh) * | 2023-01-17 | 2023-05-02 | 北京协和建昊医药技术开发有限责任公司 | 一种流动相配置装置及其配置方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
| US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5338846A (en) * | 1992-08-26 | 1994-08-16 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt |
| US5359068A (en) * | 1993-06-28 | 1994-10-25 | Pfizer Inc. | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
| WO1997017336A1 (fr) | 1995-11-07 | 1997-05-15 | Pfizer Inc. | Procedes et intermediaires de preparation de 3-(1-piperazinyl)-1,2-benzisothiazole |
| NZ508303A (en) * | 1996-05-07 | 2001-07-27 | Pfizer | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone) useful as a dopamine D2 antagonist |
| TW491847B (en) | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
-
2003
- 2003-02-14 UY UY27668A patent/UY27668A1/es not_active Application Discontinuation
- 2003-02-17 AU AU2003206035A patent/AU2003206035A1/en not_active Abandoned
- 2003-02-17 RS YU60404A patent/RS60404A/sr unknown
- 2003-02-17 KR KR1020047012980A patent/KR100773622B1/ko not_active Expired - Fee Related
- 2003-02-17 PL PL03372238A patent/PL372238A1/xx not_active Application Discontinuation
- 2003-02-17 SI SI200330811T patent/SI1476162T1/sl unknown
- 2003-02-17 EP EP03702918A patent/EP1476162B1/fr not_active Revoked
- 2003-02-17 ES ES03702918T patent/ES2283745T3/es not_active Expired - Lifetime
- 2003-02-17 DE DE60313289T patent/DE60313289T2/de not_active Revoked
- 2003-02-17 EA EA200400815A patent/EA007866B1/ru not_active IP Right Cessation
- 2003-02-17 OA OA1200400216A patent/OA12774A/en unknown
- 2003-02-17 JP JP2003569202A patent/JP4554938B2/ja not_active Expired - Fee Related
- 2003-02-17 PT PT03702918T patent/PT1476162E/pt unknown
- 2003-02-17 UA UA20040806969A patent/UA77057C2/uk unknown
- 2003-02-17 WO PCT/IB2003/000642 patent/WO2003070246A1/fr not_active Ceased
- 2003-02-17 CN CNA038042460A patent/CN1635892A/zh active Pending
- 2003-02-17 PE PE2003000168A patent/PE20030942A1/es not_active Application Discontinuation
- 2003-02-17 AT AT03702918T patent/ATE359787T1/de active
- 2003-02-17 AP APAP/P/2004/003103A patent/AP2004003103A0/en unknown
- 2003-02-17 DK DK03702918T patent/DK1476162T3/da active
- 2003-02-17 GE GE5684A patent/GEP20074030B/en unknown
- 2003-02-17 CA CA002475302A patent/CA2475302C/fr not_active Expired - Fee Related
- 2003-02-17 BR BR0307833-7A patent/BR0307833A/pt not_active IP Right Cessation
- 2003-02-17 MX MXPA04006993A patent/MXPA04006993A/es not_active Application Discontinuation
- 2003-02-17 HR HRP20040711 patent/HRP20040711A2/xx not_active Application Discontinuation
- 2003-02-17 CN CN200910261963A patent/CN101735212A/zh active Pending
- 2003-02-17 NZ NZ534443A patent/NZ534443A/en not_active IP Right Cessation
- 2003-02-18 AR ARP030100527A patent/AR038563A1/es unknown
- 2003-02-18 TW TW092103292A patent/TW200307546A/zh unknown
- 2003-02-18 MY MYPI20030564A patent/MY139523A/en unknown
- 2003-02-18 GT GT200300040A patent/GT200300040A/es unknown
- 2003-02-19 SV SV2003001485A patent/SV2004001485A/es not_active Application Discontinuation
- 2003-02-20 PA PA20038567001A patent/PA8567001A1/es unknown
-
2004
- 2004-07-05 IS IS7344A patent/IS7344A/is unknown
- 2004-07-29 IL IL163277A patent/IL163277A/en unknown
- 2004-08-05 ZA ZA200406276A patent/ZA200406276B/en unknown
- 2004-08-13 CO CO04079019A patent/CO5611138A2/es unknown
- 2004-08-17 MA MA27827A patent/MA27177A1/fr unknown
- 2004-08-19 TN TNP2004000159A patent/TNSN04159A1/fr unknown
- 2004-08-19 EC EC2004005239A patent/ECSP045239A/es unknown
- 2004-09-17 NO NO20043902A patent/NO20043902L/no not_active Application Discontinuation
-
2007
- 2007-05-10 CY CY20071100629T patent/CY1106467T1/el unknown
-
2009
- 2009-05-21 AU AU2009202008A patent/AU2009202008A1/en not_active Ceased
-
2010
- 2010-04-22 NO NO20100584A patent/NO20100584L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27177A1 (fr) | Synthese controlee de ziprasidone et compositions en contenant. | |
| MA27058A1 (fr) | Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino) ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene) methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes pour leur preparation et compositions les contenant | |
| SI1328269T1 (en) | Association of a cb1 receptor antagonist and sibutramin for treating obesity | |
| MY134559A (en) | Lactam compound to inhibit beta-amyloid peptide release or synthesis | |
| SG165314A1 (en) | Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists | |
| DE60014035D1 (de) | Zusammensetzung zur hautdesinfektion | |
| TW200740799A (en) | Alpha2C adrenoreceptor agonists | |
| WO2001081310A8 (fr) | 1-aroyle-piperidinyle benzamidines | |
| MA31963B1 (fr) | Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation | |
| HUP0302226A3 (en) | Substituted pyrrolopyridinone dervatives useful as phosphodiesterse inhibitors, their intermediates and pharmaceutical compositions containing the compounds | |
| AU3652102A (en) | Compounds and their uses | |
| IL162851A0 (en) | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists | |
| MA27181A1 (fr) | Derives de thiazole et d'oxazole qui modulent l'activite de ppar. | |
| TW200514772A (en) | Novel tetrahydropyridine derivatives | |
| MXPA05002440A (es) | Composiciones y kits para la eliminacion de compuestos irritantes de superficies corporales. | |
| AU2003228674A1 (en) | Muscarinic antagonists | |
| AP1424A (en) | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens. | |
| GB0128277D0 (en) | Pharmaceutical compositions | |
| DE60019586D1 (de) | Myostatin genpromoter und inhibierung dessen aktivierung | |
| WO2002056839A3 (fr) | Agent de lustrage nacre | |
| AU2061702A (en) | Combination of catechin and quercetin for pharmaceutical or dietary use | |
| EA201070746A1 (ru) | Фармацевтическая композиция, содержащая по меньшей мере один белковый активный ингредиент, защищенный от расщепления ферментами | |
| GB0223837D0 (en) | Improvements in and to organic compositions | |
| WO2006056696A3 (fr) | 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation | |
| UA90469C2 (ru) | Керамическая смесь для производства огнеупоров и продукт на ее основе |